The growing incidence of myeloproliferative disorders is augmenting the growth of the myeloproliferative neoplasms treatment market

 

In August 2019, Celgene Corporation announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

In January 2020, Sysmex Corporation announces its launch of the ipsogen JAK2 DX reagent. This product is a gene testing kit that measures the JAK2V617F mutation1 quantitatively, used in the diagnosis of certain hematopoietic tumors generally referred to as blood cancers, specifically polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).

In February 2019, Forbius, a clinical-stage company that develops biologics for the treatment of cancer and fibrosis, announced a collaboration agreement with the Icahn School of Medicine at Mount Sinai and the Myeloproliferative Neoplasm Research Consortium (MPN-RC).

The growing incidence of myeloproliferative disorders around the globe due to the increasing geriatric population is propelling the growth of the myeloproliferative neoplasms treatment market. John Wiley & Sons, Inc., reported annual incidence rates ranged from 0.01 to 2.61, 0.21 to 2.27, and 0.22 to 0.99 per 100,000 for PV, ET, and PMF, respectively. The combined annual incidence rates for PV, ET, and PMF were 0.84, 1.03, and 0.47 per 100,000. Changing lifestyle and growing awareness regarding the disorder is again contributing to the growth of the market. Moreover, the presence of a strong pipeline and rising drug approval from regulatory bodies is also expected to support the growth of the myeloproliferative neoplasms treatment market.

Myeloproliferative neoplasms are masses of scar tissue that begin to form in the lining of the internal organs around the time of normal birth. The myeloproliferous neoplasms generally develop into a solid mass around the organ (usually the kidneys, where they remain inactive during regular function). Although most people do not die of neoplasms, their affected organs eventually fail to function properly. Myeloproliferative neoplasms are generally diagnosed in adolescence or early adulthood and may be associated with Wilson's disease, systemic Lupus erythematosus, multiple sclerosis, etc. The main symptoms are rapid weight gain, failure to thrive, weak muscles, brittle bones, increased risk of developing infections, and difficulty breathing. Myeloproliferative neoplasms can be treated by surgery (myelogram), radiation therapy, immunotherapy, and a combination of all these treatments (many researchers believe that targeted immunotherapy is more effective than all the other approaches combined, although this remains an open question). Unfortunately, there are currently no effective medications to prevent the disease.

North America is expected to lead the global myeloproliferative neoplasms treatment market and this is attributed to the presence of well-established healthcare infrastructure in the region.